Vironexis has the potential to transform immunotherapy and the way cancer is treated in the future.
Vironexis Biotherapeutics has raised $26.0M in total funding. The most recent round was Seed. The last funding was announced in September 2024.
Vironexis Biotherapeutics's investors include Future Ventures, Capital Factory, Drive Capital, Moonshots Capital.
Vironexis Biotherapeutics is headquartered in California, United States.
Vironexis has the potential to transform immunotherapy and the way cancer is treated in the future.
Vironexis Biotherapeutics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Vironexis Biotherapeutics — Funding & Investors." VCBacked, September 12, 2024, https://www.vcbacked.co/company/vironexis-biotherapeutics. Accessed October 21, 2026.
VCBacked. (2024). Vironexis Biotherapeutics — Funding & Investors. Retrieved October 21, 2026, from https://www.vcbacked.co/company/vironexis-biotherapeutics
{{cite web |title=Vironexis Biotherapeutics — Funding & Investors |url=https://www.vcbacked.co/company/vironexis-biotherapeutics |website=VCBacked |access-date=October 21, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated